| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $5,548,612 | 17 | 100 |
| Lyons Emer | Chief Accounting Officer | 0 | $0 | 2 | $104,161 | $-104,161 |
| Whitaker Anne Clem | director | 0 | $0 | 1 | $138,168 | $-138,168 |
| Grais Linda | director | 0 | $0 | 1 | $138,169 | $-138,169 |
| O'Neill Julie | director | 0 | $0 | 1 | $150,326 | $-150,326 |
| Murray Ciaran | director | 0 | $0 | 1 | $439,803 | $-439,803 |
| Clerkin Nigel Bernard John | Chief Financial Officer | 0 | $0 | 2 | $679,947 | $-679,947 |
| McCague Eugene Pacelli | director | 0 | $0 | 3 | $737,834 | $-737,834 |
| Murphy Ronan Martin | director | 0 | $0 | 2 | $1.01M | $-1.01M |
| CLIMAX JOHN DR | director | 0 | $0 | 2 | $1.01M | $-1.01M |
| Balfe Barry Edward | Chief Executive Officer | 0 | $0 | 2 | $1.13M | $-1.13M |
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient …
Over the last 12 months, insiders at ICON Public Limited Company have bought $0 and sold $5.55M worth of ICON Public Limited Company stock.
On average, over the past 5 years, insiders at ICON Public Limited Company have bought $0 and sold $5.55M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
| 2026-11-02 | Sale | Balfe Barry Edward | Chief Executive Officer | 5,175 0.0068% | $206.66 | $1.07M | -1.40% | |
| 2026-11-02 | Sale | Clerkin Nigel Bernard John | Chief Financial Officer | 1,488 0.0019% | $206.66 | $307,503 | -1.40% | |
| 2026-11-02 | Sale | Lyons Emer | Chief Accounting Officer | 264 0.0003% | $206.66 | $54,558 | -1.40% | |
| 2026-10-23 | Sale | Lyons Emer | Chief Accounting Officer | 272 0.0003% | $182.37 | $49,604 | +10.72% | |
| 2026-09-17 | Sale | Murphy Ronan Martin | director | 5,005 0.0067% | $175.00 | $875,875 | +0.29% | |
| 2026-09-17 | Sale | McCague Eugene Pacelli | director | 3,255 0.0044% | $175.00 | $569,625 | +0.29% | |
| 2026-09-16 | Sale | CLIMAX JOHN DR | director | 5,005 0.0066% | $175.00 | $875,875 | -2.22% | |
| 2026-08-11 | Sale | Murray Ciaran | director | 2,677 0.0035% | $164.29 | $439,803 | +2.25% | |
| 2026-08-11 | Sale | Grais Linda | director | 841 0.0011% | $164.29 | $138,169 | +2.25% | |
| 2026-08-11 | Sale | Clerkin Nigel Bernard John | Chief Financial Officer | 2,267 0.0029% | $164.29 | $372,445 | +2.25% | |
| 2026-08-11 | Sale | McCague Eugene Pacelli | director | 184 0.0002% | $163.27 | $30,041 | +2.25% | |
| 2026-08-11 | Sale | Murphy Ronan Martin | director | 841 0.0011% | $164.29 | $138,168 | +2.25% | |
| 2026-08-11 | Sale | McCague Eugene Pacelli | director | 841 0.0011% | $164.29 | $138,168 | +2.25% | |
| 2026-08-11 | Sale | O'Neill Julie | director | 915 0.0012% | $164.29 | $150,326 | +2.25% | |
| 2026-08-11 | Sale | CLIMAX JOHN DR | director | 841 0.0011% | $164.29 | $138,168 | +2.25% | |
| 2026-08-11 | Sale | Whitaker Anne Clem | director | 841 0.0011% | $164.29 | $138,168 | +2.25% | |
| 2026-08-10 | Sale | Balfe Barry Edward | Chief Executive Officer | 382 0.0005% | $164.07 | $62,676 | +1.86% |
| Increased Positions | 238 | +36.79% | 12M | +16.18% |
| Decreased Positions | 282 | -43.59% | 10M | -13.27% |
| New Positions | 79 | New | 4M | New |
| Sold Out Positions | 80 | Sold Out | 2M | Sold Out |
| Total Postitions | 603 | -6.8% | 78M | +2.91% |